Eli Lilly will partner only with telehealth firms that agree to stop selling compound versions of its drug Zepbound or Novo Nordisk’s Wegovy, a move that sidelines Hims & Hers Health, Bloomberg ...

Danish pharma major Novo Nordisk and privately-held Californian firm Deep Apple Therapeutics have announced a research ...

Novo Nordisk’s drugs are being linked to an eye condition that can cause vision loss, while health tech companies made CNBC’s ...

Denmark-based multinational pharmaceutical company Novo Nordisk will be making available in the Philippines within this year ...

Denmark-headquartered Novo Nordisk (NVO) has entered into a collaboration and exclusive worldwide license agreement with ...

Advert Previous studies linked the drug to a rare eye condition known as non-arteritic anterior ischemic optic neuropathy ...

Mad Money host Jim Cramer shared his evolving view of Elon Musk’s company as he provided both praise and caution in light of ...

Deep Apple Therapeutics, Inc. announced on Wednesday a research collaboration and exclusive worldwide license agreement with ...

Insmed shares rocketed on results for a pulmonary arterial hypertension drug that exceeded Wall Street expectations.

As the healthcare industry seeks various solutions to minimize its environmental impact, many big-name companies are stepping up with ambitious strategies to lead the way.

Novo Nordisk will pay U.S. biotech Deep Apple Therapeutics up to $812 million in a partnership deal aimed at developing drugs to treat cardiometabolic diseases, including obesity.

Compounded GLP-1s are still accessible on telehealth sites, despite an agreement with Eli Lilly to cease copycat sales.